Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Celecoxib
Drug ID BADD_D00410
Description Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.[A34124]
Indications and Usage For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis
Marketing Status Prescription
ATC Code L01XX33; M01AH01
DrugBank ID DB00482
KEGG ID D00567
MeSH ID D000068579
PubChem ID 2662
TTD Drug ID D03RTS
NDC Product Code 70247-006; 42806-720; 43063-967; 72567-001; 16714-731; 59385-055; 67296-1600; 51079-199; 65162-819; 50436-0144; 46708-268; 68788-7735; 80425-0167; 65862-793; 13668-307; 69097-422; 80425-0096; 12598-9531; 69097-423; 12598-9516; 55111-898; 67296-1399; 71335-0868; 60429-460; 71610-283; 57582-032; 61919-360; 29300-373; 68180-398; 0591-3984; 70934-220; 0591-3983; 55289-451; 42571-142; 59762-1518; 51655-253; 68180-399; 62332-140; 60687-436; 57582-213; 68788-7286; 64552-4032; 53104-7533; 42806-722; 76420-009; 71209-056; 70518-1346; 65977-0052; 72189-123; 70934-213; 62704-0046; 59746-563; 77771-157; 0378-7150; 0025-1515; 71205-027; 42571-143; 70518-2748; 80425-0040; 75834-236; 65862-908; 71209-054; 63187-301; 42571-144; 63629-8156; 51927-5063; 55700-613; 13668-441; 53002-1338; 0025-1520; 50090-5178; 69367-302; 60687-447; 75834-237; 55154-7646; 50090-3183; 59762-1515; 0093-7165; 80425-0142; 43063-669; 42806-721; 62332-143; 55154-7645; 0591-3985; 68788-7264; 60505-3847; 60505-3849; 0378-7160; 55700-607; 70518-3204; 60505-3848; 71335-0936; 59762-1516; 69097-420; 0093-7170; 45865-970; 63187-633; 70934-469; 61919-837; 51079-215; 69117-0020; 65862-909; 0615-8338; 50228-156; 75834-239; 68981-025; 68180-396; 68071-4476; 69680-135; 69367-301; 65162-820; 0904-6503; 0378-7170; 52048-1995; 29300-157; 16714-734; 50268-168; 77771-156; 33342-158; 77777-115; 50228-159; 0378-7165; 70247-009; 70247-007; 69117-0021; 50090-5638; 42571-145; 69117-0022; 0093-7166; 70934-026; 51552-1461; 80425-0038; 60760-823; 43063-825; 57582-212; 72969-008; 71209-055; 53002-2338; 13668-310; 42708-016; 71205-020; 80425-0039; 67296-1608; 59746-561; 71610-584; 77771-159; 47621-024; 63187-643; 71335-0292; 0025-1530; 65162-818; 77771-158; 65862-910; 80425-0037; 67296-1345; 75834-238; 63187-562; 71335-2019; 71205-439; 71205-055; 65427-002; 60429-462; 13668-442; 62332-141; 62512-0018; 29300-158; 33342-156; 0025-1525; 68071-4392; 58159-067; 46708-267; 72241-025; 60429-461; 46708-270; 68071-4642; 70518-3292; 59762-1517; 65691-0048; 55289-475; 0904-6502; 50228-157; 57582-214; 61919-043; 69097-421; 71335-1804; 72241-023; 62332-142; 43353-257; 60760-824; 63187-079; 29300-374; 16714-733; 0591-3982; 50228-158; 43744-071; 50090-4789; 71209-057; 46708-838; 33342-155; 16714-732; 59746-564; 49706-1880; 63629-3021; 50268-169; 45865-943; 65162-817; 66651-919; 69117-0023; 72761-022; 71335-1066; 68180-395; 68724-1004; 68071-2626; 70518-2922; 65015-882; 57582-211; 33342-157; 72241-022; 45865-840; 46708-269; 65862-907; 42806-723; 59746-562; 60760-209; 0093-7306; 54245-3392; 70247-008; 61919-682; 60429-459; 72241-024
Synonyms Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Celebrex | SC 58635 | SC-58635 | SC58635
Chemical Information
Molecular Formula C17H14F3N3O2S
CAS Registry Number 169590-42-5
SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aortic valve incompetence02.07.03.001--Not Available
Aphasia19.21.01.001; 17.02.03.001--
Aplastic anaemia01.03.03.002--Not Available
Arrhythmia02.03.02.0010.001838%Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.011--Not Available
Arthralgia15.01.02.0010.004365%
Arthritis15.01.01.0010.002986%
Arthropathy15.01.01.0030.003331%Not Available
Ascites07.07.01.001; 02.05.04.002; 09.01.05.003--
Aspartate aminotransferase increased13.03.01.006--
Asphyxia22.02.02.001; 12.01.08.0110.000150%Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.002412%Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.0020.002182%
Atrioventricular block02.03.01.0020.000060%Not Available
Azotaemia20.01.01.0010.000230%Not Available
Back disorder15.03.01.0140.001263%Not Available
Back pain15.03.04.005--
Bacteriuria20.02.01.023; 11.02.01.014--Not Available
Benign prostatic hyperplasia21.04.02.001--Not Available
Bladder pain20.02.02.001--Not Available
Bleeding time prolonged13.01.02.0020.000345%Not Available
Blindness17.17.01.003; 06.02.02.0010.000919%Not Available
Blister12.01.06.002; 23.03.01.0010.002068%Not Available
Blood bilirubin increased13.03.01.008--
Blood cholesterol increased13.12.01.0020.000574%
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.0040.001723%
Blood culture positive13.08.02.002--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 24 Pages